NVUS Novus Therapeutics Inc.

4.24
+0.09  (+2%)
Previous Close 4.15
Open 4.16
Price To Book 2.75
Market Cap 40001190
Shares 9,434,243
Volume 8,910
Short Ratio
Av. Daily Volume 22,049

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial discontinued July 2016 due to poor data
Galeterone - ARMOR3-SV
Cancer - castration-resistant prostate cancer (CRPC)
Announced in August 2016 that Phase 2 trial enrollment has been discontinued.
Galeterone - ARMOR2
Xtandi (enzalutamide) refractory metastatic castration-resistant prostate cancer (mCRPC)
Phase 1 data due 2Q 2019.
OP0201- C-002
Healthy volunteers
Phase 1 data due 2Q 2019.
OP-02 (C-001)
Healthy volunteers
Phase 1 data due April 2019.
OP0201
Acute Otitis Media - adults
Phase 2a dosing has commenced - noted February 19, 2019 data due 2H 2019.
OP0201 - C-006
Acute Otitis Media - children
Phase 1 data due 2Q 2019.
OP0201 - C-001
Healthy volunteers

Latest News

  1. Novus Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Clinical Updates
  2. Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
  3. Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201
  4. Company Profile for Novus Therapeutics, Inc.
  5. Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201
  6. Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials
  7. Novus Therapeutics Doses First Patient with Acute Otitis Media in Phase 1 Study of OP0201
  8. Can We See Significant Institutional Ownership On The Novus Therapeutics, Inc. (NASDAQ:NVUS) Share Register?
  9. Novus Therapeutics Announces Formation of Scientific Advisory Board
  10. Novus Therapeutics Doses First Subjects in Phase 1 Study of OP0201
  11. Novus Therapeutics to Present at the 2018 Piper Jaffray Healthcare Conference
  12. Novus Therapeutics Reports Third Quarter 2018 Financial Results
  13. Novus Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference
  14. Novus Therapeutics to Postpone Offering of Common Stock
  15. Novus Therapeutics Announces Proposed Public Offering of Common Stock
  16. Novus Therapeutics Reports Second Quarter 2018 Financial Results
  17. Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media
  18. Novus Therapeutics Reports First Quarter 2018 Financial Results